OBJECTIVE: To determine whether statins affect type 1 interferon responses in relapsing-remitting multiple sclerosis (RRMS). DESIGN: Study effects of atorvastatin on type 1 interferon responses in Jurkat cells, mononuclear cells (MNCs) from therapy-naive patients with RRMS in vitro, and MNCs from interferon-treated RRMS patients in vivo in 4 conditions: no drug, statin only, interferon-beta only, and statin added on to interferon-beta therapy. PATIENTS: The study examined clinically stable patients with RRMS: 21 therapy-naive patients and 14 patients receiving interferon-beta with a statin. INTERVENTIONS: Statin effects on in vitro and in vivo interferon-beta-induced STAT1 transcription factor activation, expression of interferon-stimulated proteins in MNCs, and serum type 1 interferon activity. RESULTS: In vitro, atorvastatin dose dependently inhibited expression of interferon-stimulated P-Y-STAT1 by 44% (P < .001), interferon regulatory factor 1 protein by 30% (P=.006), and myxovirus resistance 1 protein by 32% (P=.004) compared with no-statin control in MNCs from therapy-naive RRMS patients. In vivo, 9 of 10 patients who received high-dose statins (80 mg) had a significant reduction in interferon-beta therapy-induced serum interferon-α/β activity, whereas only 2 of 4 patients who received medium- dose statins (40 mg) had reductions. High-dose add-on statin therapy significantly blocked interferon-beta function, with less P-Y-STAT1 transcription factor activation, and reduced myxovirus resistance 1 protein and viperin protein production. Medium doses of statins did not change STAT1 activation. CONCLUSIONS: High-dose add-on statin therapy significantly reduces interferon-beta function and type 1 interferon responses in RRMS patients. These data provide a putative mechanism for how statins could counteract the beneficial effects of interferon-beta and worsen disease.
OBJECTIVE: To determine whether statins affect type 1 interferon responses in relapsing-remitting multiple sclerosis (RRMS). DESIGN: Study effects of atorvastatin on type 1 interferon responses in Jurkat cells, mononuclear cells (MNCs) from therapy-naive patients with RRMS in vitro, and MNCs from interferon-treated RRMS patients in vivo in 4 conditions: no drug, statin only, interferon-beta only, and statin added on to interferon-beta therapy. PATIENTS: The study examined clinically stable patients with RRMS: 21 therapy-naive patients and 14 patients receiving interferon-beta with a statin. INTERVENTIONS: Statin effects on in vitro and in vivo interferon-beta-induced STAT1 transcription factor activation, expression of interferon-stimulated proteins in MNCs, and serum type 1 interferon activity. RESULTS: In vitro, atorvastatin dose dependently inhibited expression of interferon-stimulated P-Y-STAT1 by 44% (P < .001), interferon regulatory factor 1 protein by 30% (P=.006), and myxovirus resistance 1 protein by 32% (P=.004) compared with no-statin control in MNCs from therapy-naive RRMS patients. In vivo, 9 of 10 patients who received high-dose statins (80 mg) had a significant reduction in interferon-beta therapy-induced serum interferon-α/β activity, whereas only 2 of 4 patients who received medium- dose statins (40 mg) had reductions. High-dose add-on statin therapy significantly blocked interferon-beta function, with less P-Y-STAT1 transcription factor activation, and reduced myxovirus resistance 1 protein and viperin protein production. Medium doses of statins did not change STAT1 activation. CONCLUSIONS: High-dose add-on statin therapy significantly reduces interferon-beta function and type 1 interferon responses in RRMS patients. These data provide a putative mechanism for how statins could counteract the beneficial effects of interferon-beta and worsen disease.
Authors: Ken D Yamaguchi; Daniel L Ruderman; Ed Croze; T Charis Wagner; Sharlene Velichko; Anthony T Reder; Hugh Salamon Journal: J Neuroimmunol Date: 2008-02-14 Impact factor: 3.478
Authors: Johann Sellner; Isabell Greeve; Oliver Findling; Christian P Kamm; Carsten Minten; Britta Engelhardt; Denis Grandgirard; Stephen L Leib; Heinrich P Mattle Journal: Neurochem Int Date: 2008-04-20 Impact factor: 3.921
Authors: Anthony T Reder; Sharlene Velichko; Ken D Yamaguchi; Kemal Hamamcioglu; Karin Ku; Johanna Beekman; T Charis Wagner; H Daniel Perez; Hugh Salamon; Ed Croze Journal: J Interferon Cytokine Res Date: 2008-05 Impact factor: 2.607
Authors: Yogita Ghodke-Puranik; Molly Imgruet; Jessica M Dorschner; Prakriti Shrestha; Kaci McCoy; Jennifer A Kelly; Miranda Marion; Joel M Guthridge; Carl D Langefeld; John B Harley; Judith A James; Kathy L Sivils; Timothy B Niewold Journal: Cytokine Date: 2019-01-24 Impact factor: 3.861
Authors: S N Kariuki; Y Ghodke-Puranik; J M Dorschner; B S Chrabot; J A Kelly; B P Tsao; R P Kimberly; M E Alarcón-Riquelme; C O Jacob; L A Criswell; K L Sivils; C D Langefeld; J B Harley; A D Skol; T B Niewold Journal: Genes Immun Date: 2014-10-23 Impact factor: 2.676
Authors: B S Chrabot; S N Kariuki; M I Zervou; X Feng; J Arrington; M Jolly; D T Boumpas; A T Reder; G N Goulielmos; T B Niewold Journal: Genes Immun Date: 2013-08-22 Impact factor: 2.676